Genprex 경영진

경영진 기준 점검 3/4

Genprex CEO는 Ryan Confer, Sep2016 에 임명되었습니다 의 임기는 9.67 년입니다. 총 연간 보상은 $728.87K, 65.9% 급여 및 34.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $10.90K 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 4.5 년과 5.8 년입니다.

핵심 정보

Ryan Confer

최고경영자

US$728.9k

총 보수

CEO 급여 비율	65.86%
CEO 재임 기간	9.7yrs
CEO 지분 보유율	0.1%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	5.8yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Aug 16

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Genprex (NASDAQ:GNPX) stock rose ~13% on Aug. 15 after the company said that the Safety Review Committee (SRC) approved continuation of a phase 1/2 trial of Reqorsa in combination with AstraZeneca's Tagrisso (osimertinib) to treat patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. The SRC decision followed a review of the first group of patients in the phase 1 portion of the phase 1/2 study called Acclaim-1. "The SRC approval to advance Acclaim-1 to the higher dose in the second cohort of patients is an important milestone that further supports REQORSA's safety profile and brings us one step closer to bringing this potentially ground-breaking gene therapy approach to treating NSCLC to the patients who need it most," said Genprex Chief Medical Officer Mark Berger. The trial includes up to three sequential dose escalation groups, the company said in an Aug. 15 press release.

분석 기사 • Jun 14

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

분석 기사 • Feb 09

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Nov 19

Genprex: Limited Clinical Data To Justify Risk

GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes. REQORSA—the company's main pipeline molecule—is targeting the Non-Small-Cell Lung Cancer Market. GNPX's share price is currently trading at around $2 after a quick fall from grace (from $15/share) following its IPO in early 2018. Although a low share price may be an attractive entry point, I believe the company has not yet produced any reliable proof of the clinical efficacy of its therapy. In this article, I will argue a neutral position on GNPX discussing the company's technology, market, and clinical data, to present a balanced view on both risk and opportunity.

분석 기사 • Oct 27

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

분석 기사 • Jun 11

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO 보수 분석

Ryan Confer의 보수는 Genprex의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$17m
Dec 31 2025	US$729k	US$480k	-US$16m
Sep 30 2025	n/a	n/a	-US$17m
Jun 30 2025	n/a	n/a	-US$18m
Mar 31 2025	n/a	n/a	-US$19m
Dec 31 2024	US$542k	US$462k	-US$21m
Sep 30 2024	n/a	n/a	-US$23m
Jun 30 2024	n/a	n/a	-US$26m
Mar 31 2024	n/a	n/a	-US$28m
Dec 31 2023	US$887k	US$426k	-US$31m
Sep 30 2023	n/a	n/a	-US$31m
Jun 30 2023	n/a	n/a	-US$30m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$1m	US$393k	-US$24m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$1m	US$345k	-US$21m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$18m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$1m	US$351k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$1m	US$300k	-US$11m

보상 대 시장: Ryan의 총 보수(USD728.87K)는 US 시장에서 비슷한 규모 기업의 평균(USD647.34K) 수준입니다.

보상과 수익: Ryan의 보상은 회사가 적자임에도 증가했습니다.

CEO

Ryan Confer (43 yo)

9.7yrs

재임 기간

US$728,871

보수

Mr. Ryan M. Confer, M.S. has been the Chief Financial Officer of Genprex, Inc. since September 2016 and serves as its Chief Executive Officer, President and Director since May 08, 2024. Mr. Confer served a...

리더십 팀

이름	직위	재임 기간	보수	지분
Ryan Confer	President	9.7yrs	US$728.87k	0.13% $ 10.9k
Mark Berger	Chief Medical Officer	4.7yrs	US$688.60k	0.071% $ 5.9k
David Schloss	Senior Vice President of Human Resources	4.3yrs	데이터 없음	데이터 없음
Thomas Gallagher	Senior Vice President of Intellectual Property & Licensing	5.7yrs	데이터 없음	데이터 없음
Suzanne Thornton-Jones	Senior Vice President of Regulatory Affairs & Quality	2.8yrs	데이터 없음	데이터 없음
Celina Laney	Chief of Staff	no data	데이터 없음	데이터 없음
Greg Jancarik	Senior Director & Corporate Controller	less than a year	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

경험이 풍부한 관리: GNPX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 4.5 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Ryan Confer	President	2yrs	US$728.87k	0.13% $ 10.9k
Brent Longnecker	Independent Director	6.2yrs	US$88.09k	0.0015% $ 124.0
James E. Rothman	Strategic Advisor to the Board of Directors	13.8yrs	데이터 없음	데이터 없음
Jack Roth	Chairman of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
Pasi Antero Janne	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
George Peoples	Member of Clinical Advisory Board	5.3yrs	데이터 없음	데이터 없음
Shu Kam Mok	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
George Simon	Member of Scientific & Medical Advisory Board	no data	데이터 없음	데이터 없음
William Wilson	Independent Director	6.2yrs	US$78.09k	0.0015% $ 124.0
Jose Antonio Toscano	Independent Non-Executive Chairman	6.2yrs	US$103.09k	0.0015% $ 124.0
George Gittes	Member of Scientific Advisory Board	5.5yrs	데이터 없음	데이터 없음
Michael Morse	Member of Clinical Advisory Board	5.3yrs	데이터 없음	데이터 없음

5.8yrs

평균 재임 기간

65yo

평균 나이

경험이 풍부한 이사회: GNPX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 5.8 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/20 04:32
종가	2026/05/20 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Genprex, Inc.는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
James Molloy	Alliance Global Partners

Genprex 경영진

경영진 기준 점검 3/4

핵심 정보

최근 경영진 업데이트

Genprex, Inc., Annual General Meeting, Aug 15, 2025

Genprex, Inc Announces Executive Changes

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

High number of new and inexperienced directors

Recent updates

Genprex Inc. Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes

Genprex Inc Receives Patent Grant from the Israel Patent Office for Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Inc Announces Positive Clinical Data on Reqorsa Gene Therapy At Asco Annual Meeting

Genprex, Inc. Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer

New major risk - Financial position

Genprex, Inc. to Present Positive Preclinical Data on Reqorsa Gene Therapy for Lung Cancer At the 2026 AACR Annual Meeting

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex, Inc. Announces Ip Australia's Intent to Grant Patent for Reqorsa®? Gene Therapy in Combination with Pd-L1 Antibodies to Treat Cancers

Genprex, Inc. Provides Clinical Update on Diabetes Gene Therapy Program

Genprex Regains Compliance with the Bid Price Requirement and Receives Extension to Regain Compliance with Nasdaq Stockholders Equity Requirement

Genprex, Inc. Announces the Publication of Data from Its Acclaim-1 Phase 1 Clinical Trial of Reqorsa®? Gene Therapy in Combination with Tagrisso®? (Osimertinib) in Patients with Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex, Inc. has filed a Follow-on Equity Offering in the amount of $3.40002 million.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer At the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex, Inc. has filed a Follow-on Equity Offering in the amount of $2.731003 million.

Genprex Inc Receives Exception to Regain Compliance with Nasdaq Listing Requirements

New major risk - Share price stability

Genprex, Inc. Receives Non-Compliance Letter from Listing Qualifications Staff of the Nasdaq Stock Market

Genprex, Inc. Receives Notice of Allowance for Multiple Patents for Reqorsa®? Gene Therapy with Pd-L1 and Pd-1 Antibodies to Treat Cancers

Genprex, Inc. has withdrawn its Follow-on Equity Offering.

Genprex, Inc., Annual General Meeting, Aug 15, 2025

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy At the 2025 American Diabetes Association 85Th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System

Genprex Confirms Regains Compliance with Nasdaq Listing Requirements

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa®? Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer At the 2025 Aacr Annual Meeting

Genprex Selects to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa®? Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex, Inc. announced delayed annual 10-K filing

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System Is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Genprex, Inc. Announces First Patient Has Been Enrolled and Dosed in the Phase 2 Expansion Portion of the Company’S Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

New major risk - Shareholder dilution

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer

Genprex, Inc. announced delayed 10-Q filing

No longer forecast to breakeven

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

Price target increased to US$6.23

High number of new and inexperienced directors

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans